Quarterly ResultMay 5, 2026, 04:12 PM
GRAIL Q1 Revenue +28% to $40.8M; Galleri Revenue +37% to $39.8M
AI Summary
GRAIL reported strong first-quarter 2026 financial results, with total revenue increasing 28% year-over-year to $40.8 million and Galleri revenue growing 37% to $39.8 million. The company also saw a 50% rise in Galleri test volume to over 56,000. GRAIL announced plans to integrate the Galleri test into Epic's electronic health record platform to expand nationwide access and confirmed that its Premarket Approval application for Galleri was accepted by the FDA for review. Additionally, new data from the NHS-Galleri trial and PATHFINDER 2 study will be presented at the 2026 ASCO Annual Meeting.
Key Highlights
- Total revenue increased 28% year-over-year to $40.8 million.
- Galleri revenue grew 37% year-over-year to $39.8 million.
- Galleri test volume rose 50% year-over-year to over 56,000.
- Net loss improved 12% to $(93.2) million.
- Premarket Approval (PMA) application for Galleri accepted by FDA for review.
- Planned integration of Galleri test into Epic EHR platform by end of 2026.
- New data from NHS-Galleri and PATHFINDER 2 studies to be presented at ASCO.
- Cash, cash equivalents, and short-term marketable securities totaled $823.1 million.